Introduction
The A20 structure and expression features
The biological functions of A20
NF-κB inhibitory factor
Regulation in innate and adaptive immunity
Tumor suppressor
Molecular mechanisms of the A20 biological functions
Regulation of A20 expression
A20 gene alterations in lymphocytic malignancy
A20 deletion and mutation
Diagnosis | Number of cases | Deletion (%) | Mutation (%) | Location | Reference |
---|---|---|---|---|---|
cHL | 36 | 44 | OUT, ZF domain | [47] | |
EBV+ | 16 | 12.5 | - | ||
EBV- | 20 | 70 | - | ||
NSHL | 15 | 33.3 | Exons 3, 4, and 7 | [28] | |
other HL | 27 | 26 | [48] | ||
MZL | 32 | 2 | 19 | Exons 3, 6, and 7 | [46] |
EMZL | 11 | 18 | Exons 3 and 7 | ||
NMZL | 9 | 33 | Exons 3, 6, and 7 | ||
sMZL | 12 | 8 | Exon 6 | ||
sMZL | 46 | 6.5 | 6.5 | - | [49] |
MALTL | 30 | 6 | 17.6 | C1777T; C811T; G460T/△CT1877-8 | [50] |
87 | 21.8 | Exons 3, 5, 6, 7, and 9 | [28] | ||
64 | 17.2 | - | [45] | ||
9 | 11 | Exon 3 | [1] | ||
DLBCL | 64 | 7.8 | 2 | [28] | |
102 | 38 | - | [45] | ||
GCB type | 18 | 22.2 | - | [45] | |
ABC type | 28 | 50 | - | [45] | |
GCB type | 44 | 2.3 | - | [33] | |
ABC type | 37 | 32 | 23 | - | [33] |
non-GC/NC-DCBCL | 20 | 34 | 22 | - | [33] |
MCL | 35 | 0 | - | [28] | |
29 | 31 | - | [45] | ||
FL | 52 | 1.9 | - | [28] | |
23 | 26 | - | [45] | ||
PMBL | 14 | 36 | - | [47] | |
Burkitt L | 19 | 10.5 | - | [45] | |
NK L | 27 | 18.5 | - | [45] | |
ATLL | 68 | 10.3 | - | [45] | |
PTCL-u | 51 | 9.8 | - | [45] | |
CTCL | 13 | 46 | - | [51] | |
ARL | 33/19 | 18 | 16 | - | [52] |
PCNSL | 32 | 3 | - | [53] | |
spinal cord DLBCL | 10 | 10 | - | [53] | |
CLL | 48 | 27 | 2 | - | |
55 | 0 |